Category: Press Releases

Genprex Demonstrates Growth and Expansion Through Recent Achievements

Company’s recent performance sets path for future milestones, commercialization

Read More

Genprex Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program

Genprex's newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies.

Read More

Genprex Begins Next Phase of Drug Branding Program

Genprex has initiated the first phase of branding its lead drug candidate and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (USAN) Council.

Read More

Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination With Immunotherapy for Non-Small Cell Lung Cancer

Genprex today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Read More

Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria
Read More

Genprex Retains Addison Whitney for Drug Nomenclature Branding

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of
Read More

Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting

Genprex reported that its collaborators from The University of Texas MD Anderson Cancer Center presented positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a poster presented at the American Association of Cancer Research Meeting 2019.

Read More

Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018

Genprex today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission.

Read More

Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City

Genprex today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019.

Read More

Genprex Strengthens Senior Team and Continues to Advance Operations

Genprex announced that it is continuing to grow its senior team with the hiring of Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing, effective immediately.

Read More

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link